Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces that MB097 is now in pre-clinical development for treatment of patients not responding to anti-PD1 therapy. Clinical trials are due to begin in 2022. […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has entered into a research collaboration agreement with Roche for the discovery of a […]
There’s a lot of interest right now in how different microbiomes–like the one made up of all the bacteria in our guts–could be harnessed to boost human health and cure disease. But Daniel Segrè has […]
Researchers from Yonsei University in South Korea have found that certain commensal bacteria that reside in the human intestine produce compounds that inhibit SARS-CoV-2. Previous clinical findings have shown that some patients with moderate to […]
Encouraging results are obtained from research carried out to develop novel treatments for inflammatory bowel disease, an intractable hypersensitive immune disease of the intestine, and multiple sclerosis, an autoimmune disease of the brain and spinal […]
New findings from Cleveland Clinic researchers show for the first time that the gut microbiome impacts stroke severity and functional impairment following stroke. The results, published in Cell Host & Microbe, lay the groundwork for […]
Gusto Global, a leading microbiome discovery platform company focused on restoring a healthy microbiome, has developed novel consortia of bacteria that shows promise as a “breakthrough” therapy for treating Crohn’s disease and ulcerative colitis in […]
Osel Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, announced that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented […]
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the completion of its target enrollment […]
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application. SER-155 is an […]
About 12,000 bacteria and viruses collected in a sampling from public transit systems and hospitals around the world from 2015 to 2017 had never before been identified, according to a study by the International MetaSUB […]